Total
0
Shares
Image Sourced Shutterstock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Konekt Limited has obtained the Disability Employment Services business of Artius
  • The newly obtained services will be delivered across five locations with the contract lasting until 2023
  • However, the purchase is subject to consent by the Commonwealth Department of Social Services and other standard conditions
  • Konekt will continue to focus on its organic growth and other acquisition opportunities

Konekt Limited is one of the top gainers this morning, after it announced it had obtained the Disability Employment Services (DES) business of Artius.

Konekt is an ASX-listed company and the largest private sector provider of organisational health and risk management solutions.

Its aim is to help organisations minimise the impact of workplace injury and related workplace costs, resulting in reduced workers’ compensation premiums.

Artius is Queensland’s leading provider of health, employment, community and training services. Its mission is to help people, businesses and communities reach their potential.

Konekt CEO Damian Banks is pleased to work with Artius and expand Konekt’s reach.

“We are delighted to welcome the DES business of Artius to our organisation, expanding our position in regional Queensland, servicing local customers from five locations in Ipswich, Goodman, Warwick and Stanthorpe,” Damian said.

“This acquisition will increase Konekt’s DES regional footprint from 16 to 18 regions, and expand our services to include both Disability Management Services (DMS) and Employment Support Services (ESS) for the first time,” he said.

The newly obtained services will be delivered across five locations with the contract period lasting until 2023.

This purchase will be funded from cash reserves with a small revenue earn-out based on future performances, and it’s expected to contribute $1.1 million of revenue to Konekt in FY20.

However, the purchase is subject to consent by the Commonwealth Department of Social Services and other standard conditions, completion of all consent and requirements is expected during this current quarter.

Konekt will continue to focus on its organic growth and other acquisition opportunities that will strengthen its position and value for customers, staff and shareholders.

KKT by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - MD and CEO Phillip Lynch

" Race Oncology (ASX:RAC) secures sixth US patent for Zantrene

Race Oncology (RAC) has locked in its sixth US patent for its cancer drug, Zantrene.
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.